Dr. Planchard on Dabrafenib/Trametinib Combo in Advanced NSCLC

David Planchard, MD, PhD
Published: Wednesday, Jun 15, 2016



David Planchard, MD, PhD, Department of Medical Oncology, Thoracic Unit, Institut Gustave Roussy, discusses a phase II trial examining the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in pretreated patients with BRAF V600E-mutant advanced non–small cell lung cancer (NSCLC).

In the study, patients continued treatment with the doublet regimen until disease progression or unacceptable toxicity. The overall response rate, which was the primary endpoint of the trial, was 63% with assessments by both investigators and an independent review committee, Planchard says. The disease-control rate was approximately 80%, which demonstrates that the combination can benefit this patient population.

Among the responders, 50% of patients had ongoing responses, Planchard adds. Additionally, the median progression-free survival rate was 9.7 months, according to investigator assessment.


David Planchard, MD, PhD, Department of Medical Oncology, Thoracic Unit, Institut Gustave Roussy, discusses a phase II trial examining the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in pretreated patients with BRAF V600E-mutant advanced non–small cell lung cancer (NSCLC).

In the study, patients continued treatment with the doublet regimen until disease progression or unacceptable toxicity. The overall response rate, which was the primary endpoint of the trial, was 63% with assessments by both investigators and an independent review committee, Planchard says. The disease-control rate was approximately 80%, which demonstrates that the combination can benefit this patient population.

Among the responders, 50% of patients had ongoing responses, Planchard adds. Additionally, the median progression-free survival rate was 9.7 months, according to investigator assessment.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x